Table 2 Clinicopathological features of patients in the non-recurrence and recurrence groups
From: Prognostic factors in patients with HBV-related hepatocellular carcinoma following hepatic resection
Characteristic | Non-Recurrence (n = 113) | Recurrence (n = 104) | P value |
|---|---|---|---|
Gender, n (%) (total cohort n = 217) | |||
 male | 49 (43.36) | 51 (49.04) | 0.402 |
 female | 64 (56.64) | 53 (50.96) |  |
Age (years), mean ± sd | 56.46 (10.60) | 55.76 (8.86) | 0.604 |
HCV, n (%) | |||
 no | 111 (98.23) | 99 (95.19) | 0.264 |
 yes | 2 (1.77) | 5 (4.81) |  |
Platelets × 103, median (range), n = 384 | 198.5 (57, 465) | 179.5 (76, 568) | 0.068 |
AFP-pre (ng/mL), median (range), n = 325 | 15.2 (0.89, 60,500) | 17.03 (1.1, 82,392) | 0.572 |
AFP-post (ng/mL), median (range), n = 226 | 2.8 (0.83, 5271) | 3.8 (0.9, 19,629) | 0.045 |
Tumor size (cm), median (range), n = 386 | 4.3 (0.6, 26.5) | 5 (0.5, 18) | 0.511 |
  < 5 | 63 (55.75) | 57 (55.34) | 0.951 |
  ≥ 5 | 50 (44.25) | 46 (44.66) |  |
Number of tumors, n (%), n = 382 | |||
 solitary | 94 (85.45) | 72 (69.23) | 0.004 |
 multiple | 16 (14.55) | 32 (30.77) |  |
Microvascular invasion, n (%), n = 382 | |||
 no | 89 (80.91) | 81 (77.88) | 0.584 |
 yes | 21 (19.09) | 23 (22.12) |  |
Stage, n (%) | |||
 I | 77 (68.14) | 61 (58.65) | 0.147 |
 II or higher | 36 (31.86) | 43 (41.35) |  |
Resection margin, n (%), n = 325 | |||
 free margin | 89 (94.68) | 87 (95.60) | 0.999 |
 positive margin | 5 (5.32) | 4 (4.40) |  |
Operation type, n (%) | |||
 non-anatomical | 69 (61.06) | 60 (57.69) | 0.614 |
 anatomical | 44 (38.94) | 44 (42.31) |  |
Preoperative neoadjuvant, n (%), n = 289 | |||
 no | 44 (48.89) | 48 (64.86) | 0.040 |
 yes | 46 (51.11) | 26 (35.14) |  |
Platelet-to-lymphocyte ratio, median (range), n = 365 | 106.6 (46.3, 432.8) | 91.2 (30.9, 290.7) | 0.128 |
Prognostic nutritional index, median (range), n = 370 | 89.12 (0.34, 265.26) | 91.9 (0.41, 245.02) | 0.764 |
Neutrophil-to-lymphocyte ratio, median (range), n = 361 | 1.78 (0.67, 8.11) | 1.76 (0.33, 10.62) | 0.770 |
Antiviral treatment | |||
 no | 30 (26.55) | 35 (33.65) | 0.254 |
 yes | 83 (73.45) | 69 (66.35) |  |
Antiviral drug | |||
 Adefovir | 4 (3.54) | 3 (2.88) | 0.999 |
 Lamivudine | 66 (58.41) | 59 (56.73) | 0.254 |
 Tenofovir | 28 (25.66) | 15 (14.42) | 0.021 |
 Entecavir | 10 (8.85) | 10 (9.62) | 0.846 |
Antiplatelet treatment (ASA + Clopidogrel) | |||
 no | 103 (91.15) | 96 (92.31) | 0.757 |
 yes | 10 (8.85) | 8 (7.69) |  |